


INTESTINAL RESEARCH

See “Seven days triple therapy for eradication of *Helicobacter pylori* does not alter the disease activity of patients with inflammatory bowel disease” on page 609-618.



Supplementary Fig. 1. Study flow chart.

Supplementary Table 1. Definition-Based Disease Exacerbation 2 and 6 Months after *Helicobacter pylori* Eradication or Observation in UC and CD Patients

	Eradication group	Non-eradication group	OR (95% CI)	P-value
UC (n=378)				
2 Months	11 (8.7)	14 (5.6)	1.76 (0.71–3.65)	0.255
6 Months	15 (11.8)	21 (8.4)	1.47 (0.73–2.95)	0.281
CD (n=51)				
2 Months	1 (5.9)	0	-	-
6 Months	2 (11.8)	1 (2.9)	4.40 (0.37–52.40)	0.207

Values are presented as number (%).

Supplementary Table 2. Changes in IBD Disease Activity after *Helicobacter pylori* Eradication by Clinical Activity Indices

	Exacerbated	Unchanged	Improved	P-value
2 Months				
Eradication	8	106	2	0.236
Non-eradication	7	223	4	
6 Months				
Eradication	14	99	2	0.100
Non-eradication	13	208	7	